{
    "nctId": "NCT01227408",
    "briefTitle": "Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer",
    "officialTitle": "Phase II Clinical Trial of Neoadjuvant Weekly Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* SWOG performance status of 0-2\n* Projected life expectancy of at least 3 months\n* Female age 18 years and over\n* Provision of informed consent prior to any study-related procedures.\n* Hormone receptor positive or negative tumor\n* Her 2 neu negative tumor\n* Negative pregnancy test for women of childbearing potential\n* Patients must agree to use some form of contraception while on this study at initiation and for the duration of participation in the study. Sexually active males must also use a reliable and appropriate method of contraception. Post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.\n* ANC \\> 1500, Platelet count \\> 100,000, Hemoglobin \\> 9.0\n* Serum creatinine \\< 1.5 mg/dl\n* Hepatic function: Patients must have adequate liver functions: AST or ALT \\< 2.5 X upper limit of normal (ULN), alkaline phosphatase \\< 2.5 X upper limit of normal. Serum Bilirubin \\< 1.5 mg\n* Peripheral neuropathy grade 0-1\n* No other concomitant therapy directed at the cancer is allowed.\n\nExclusion Criteria:\n\n* Serum bilirubin \\> 1.5 the upper limit of reference range (ULRR)\n* Serum creatinine \\>1.5\n* Prior therapy for this tumor.\n* Clinical Congestive Heart Failure\n* Women who are currently pregnant or breast feeding.\n* Receipt of any investigational agents within 30 days prior to commencing study treatment\n* Prior radiation must not have included \u2265 30% of major bone marrow containing areas (pelvis, lumbar spine)\n* No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, lobular carcinoma in-situ of the breast (LCIS), or any other cancer from which the patient has been disease-free for 5 years. Patients with prior invasive breast cancer or ductal carcinoma in-situ (DCIS) are eligible if they have been disease free for 5 years and did not receive prior treatment with doxorubicin and/or a taxane.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}